English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Biogen Exercises Option With Ionis to Develop and Commercialize Investigational ASO for SMA
Biogen, Inc. and Ionis Pharmaceuticals, Inc. announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306. The companies have a broad strategic collaboration to develop novel therapies to treat neurological disorders. BIIB115 is an investigational antisense oligonucleotide (ASO) in development for spinal muscular atrophy (SMA) that may have the potential to help address additional unmet needs of patients as well as to be administered at extended dosing intervals. Biogen plans to advance BIIB115 to clinical trials to investigate safety, tolerability, pharmacokinetics, and efficacy.
“Combining Biogen’s expertise in neurology with Ionis’ leadership in antisense technology has led to SPINRAZA® (nusinersen) being a foundation of care in SMA,” said Toby Ferguson, M.D., Ph.D., Vice President and Head of the Neuromuscular Development Unit at Biogen.
BookmarkRelated Content
-
Biogen to Launch Study of Higher Spinraza Dose in Patients With Later Onset SMABiogen announced it intends to initiate ...
-
Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiat...Spinal muscular atrophy (SMA) is an auto...
-
New Treatment Can Help Fresno Infant With Rare Genetic DisorderA Fresno family is holding onto hope aft...
-
Comparative All-Cause Mortality Among a Large Population of Patients With Spinal Muscular Atrophy Versus Matched Con...Introduction: There is little informatio...
-
FDA Lifts Partial Clinical Hold on Novartis’ SMA Drug ProgrammeThe US Food and Drug Administration (FDA...
-
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022Scholar Rock, a clinical-stage biopharma...
-
Karen S. Chen, PhDKaren Chen is the Chief Executive Office...
Powered by
In partnership with
